New PET tracer could reveal hidden immune clues in lung cancer

NCT ID NCT05933239

Recruiting now Diagnosis Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Jun 02, 2026 · Last updated Jun 18, 2026 · Updated 2 times

Summary

This study tests a new imaging agent (68GaNOTA-anti-MMR-VHH2) that attaches to certain immune cells (macrophages) in lung tumors. About 20 adults with non-small cell lung cancer scheduled for surgery will receive a PET scan with this tracer before their operation. The goal is to see if the scan matches lab tests of the removed tumor tissue, which could help doctors better understand and diagnose lung cancer in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Universitair Ziekenhuis Brussel
RECRUITING

Jette, Brussels Capital, 1090, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER NON SMALL CELL LUNG CANCER